Fondaparinux Disease Interactions
There are 6 disease interactions with fondaparinux:
- Hepatic impairment
- Renal disease
- Valvular heart disease
- Bacterial endocarditis
Factor Xa inhibitors (applies to fondaparinux) bleeding
Major Potential Hazard, Moderate plausibility.
The use of factor Xa inhibitors is contraindicated in patients with active pathological bleeding. Its use increases the risk of bleeding and can cause serious or fatal bleeding. Caution is recommended when prescribing these agents to patients at increased risk of bleeding. When using these agents, the risk of thrombotic events should be weighed against the risk of bleeding.
Factor Xa inhibitors (applies to fondaparinux) hepatic impairment
Major Potential Hazard, Moderate plausibility. Applicable conditions: Liver Disease
In general, the manufacturer recommends avoiding the use of factor Xa inhibitors in patients with moderate and severe hepatic impairment or with any hepatic disease associated with coagulopathy as drug exposure and bleeding risk may be increased.
Factor Xa inhibitors (applies to fondaparinux) renal disease
Major Potential Hazard, Moderate plausibility. Applicable conditions: Renal Dysfunction
Some factor Xa inhibitors such as rivaroxaban and fondaparinux should be avoided in patients with CrCl <30 mL/min. Observe closely and promptly evaluate any signs or symptoms of blood loss in patients with CrCl 30 to 50 mL/min. Treatment should be discontinued in patients who develop acute renal failure while on treatment with these drugs.
Factor Xa inhibitors (applies to fondaparinux) valvular heart disease
Major Potential Hazard, Moderate plausibility. Applicable conditions: Prosthetic Heart Valves
The use of factor Xa inhibitors is not recommended in patients with prosthetic heart valves as no studies have been conducted for safety and efficacy.
Fondaparinux (applies to fondaparinux) bacterial endocarditis
Major Potential Hazard, Moderate plausibility. Applicable conditions: Infectious Endocarditis
The manufacturers state that bacterial endocarditis is a contraindication for the use of fondaparinux injection.
Fondaparinux (applies to fondaparinux) thrombocytopenia
Moderate Potential Hazard, Moderate plausibility.
Thrombocytopenia can occur with the administration of fondaparinux. Caution should be used when administered to patients with preexisting thrombocytopenia. Thrombocytopenia of any degree should be monitored closely and treatment should be discontinued if the platelet count falls below 100,000/mm3.
Fondaparinux drug interactions
There are 161 drug interactions with fondaparinux
More about fondaparinux
- Side Effects
- During Pregnancy or Breastfeeding
- Dosage Information
- Drug Interactions
- Pricing & Coupons
- En Español
- 7 Reviews
- Drug class: factor Xa inhibitors
Related treatment guides
Drug Interaction Classification
|Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.|
|Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.|
|Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.|
|No interaction information available.|